ASO Visual Abstract: Health Care Costs of Laparoscopic Versus Open Surgery for Rectal Cancer Patients in the First 12 Months: A Secondary End-Point Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial (ALaCaRT)

21 Background: There is an increasing need to evaluate the quality and cost of care within oncology. Estimating health care costs for patients who are lost to follow-up or censored often results in underestimating costs, biasing comparative assessments. This study compared traditional costing approaches with that of KMSA methods for patients treated for metastatic bladder cancer. Methods: Advanced metastatic bladder cancer patients receiving second line chemotherapy were identified from the Truven Health MarketScan Claims Databases (04/2011 to 09/2014). All-cause health care costs represent the total dollars paid to all providers of care regardless of diagnosis and were inflated to 2014 USD. Total, medical, pharmacy, and site-of-care costs from treatment initiation to death, end-of-enrollment, or end-of-study period were compared using the KMSA and traditional methods. In KMSA, the follow-up period is divided into small uniform intervals; total cost in each interval is then multiplied by the individual patient’s survival probability at the beginning of each interval and then summed across the intervals. Results: The censoring rate of patients’ follow-up was 49%. The mean per patient total health care captured by traditional method was only 72% of the total cost estimated by KMSA method or $32,930 less per patient. Overall, underestimates ranged from 28% to 41% with pharmacy, ER, and lab service costs underestimated the largest when using the traditional method. Conclusions: The KMSA produced estimates more reflective of actual patient-level health care costs in this claims-based observational cancer study compared to traditional methods by accounting for the effect of censoring. Researchers should consider KMSA when evaluating and comparing costs of care in the presence of variable follow-up.[Table: see text]

Download Full-text

Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2015.21.9.841 ◽

2015 ◽

Vol 21 (9) ◽

pp. 841-843 ◽

Cited By ~ 1

Author(s):

Elizabeth A. MacLean ◽

Rickard Sandin ◽

Jack Mardekian

Keyword(s):

Health Care ◽

Cancer Patients ◽

Health Care Costs ◽

Renal Cancer ◽

Care Costs

Download Full-text

PCN112 Estimating Resources Utilization and Health Care Costs Related to Colorectal Cancer Patients in Saudi Arabia

Value in Health ◽

10.1016/j.jval.2020.08.249 ◽

2020 ◽

Vol 23 ◽

pp. S442-S443

Author(s):

B. Balkhi ◽

A. Alharbi ◽

M. Al Najjar ◽

A. Alghamdi ◽

Y. AlRuthia ◽

...

Keyword(s):

Colorectal Cancer ◽

Health Care ◽

Saudi Arabia ◽

Cancer Patients ◽

Health Care Costs ◽

Colorectal Cancer Patients ◽

Care Costs

Download Full-text

Influence on the Health of the Partner Affected by Tumor Disease in the Wife or Husband Based on a Population-Based Register Study of Cancer in Sweden

Journal of Clinical Oncology ◽

10.1200/jco.2008.21.6788 ◽

2009 ◽

Vol 27 (28) ◽

pp. 4781-4786 ◽

Cited By ~ 47

Author(s):

Katarina Sjövall ◽

Bo Attner ◽

Thor Lithman ◽

Dennis Noreen ◽

Barbro Gunnars ◽

...

Keyword(s):

Prostate Cancer ◽

Health Care ◽

Cancer Patients ◽

Health Care Costs ◽

Cancer Diagnosis ◽

Health Care Use ◽

Psychiatric Diagnoses ◽

Male Partners ◽

Costs Of Care ◽

Care Costs

Purpose To examine health care use and health care costs among partners of persons with cancer. Patients and Methods Partners of patients with colon, rectal, lung, breast, and prostate cancer (N = 11,076) were identified via linked data from the Tumor Registry of Southern Sweden and Census Registry of Sweden. Health care use, total costs of health care, and diagnosis of the partner were studied before and after diagnosis of the cancer patient. Results Health care use for partners increased in terms of in-patient care after the cancer diagnosis. A significant increase was seen the second year for partners of patients with colon cancer (risk ratio [RR], 1.55; 95% CI, 1.28 to 1.87) and lung cancer (RR, 1.50; 95% CI, 1.26 to 1.79). Psychiatric diagnoses increased after the cancer diagnosis in the total sample, with a significant increase for partners of colon (RR, 2.66; 95% CI, 1.71 to 4.22), lung (RR, 3.16; 95% CI, 2.23 to 4.57), and prostate cancer patients (RR, 1.68; 95% CI, 1.32 to 2.15). Costs of care increased more than the consumer price index the two years after the cancer diagnosis. Costs of care increased most for male partners and especially for younger male partners (age 25 to 64 years) of patients with colon, rectal, and lung cancers. Conclusion The results showed increased health care costs and an increase in psychiatric diagnoses after the cancer diagnosis among partners of cancer patients. Further research is needed to learn more about the situation of the partner and to identify persons at risk of psychiatric morbidity. Knowledge is also needed on how to support the partner in the most efficient way.

Download Full-text